[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100476776":3},{"organization":4,"armGroups":7,"interventions":36,"overallOfficials":69,"centralContacts":73,"locations":81,"responsibleParty":274,"collaborators":276,"id":279,"slug":280,"hasResults":281,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":281,"sex":287,"minAge":288,"maxAge":289,"enrollmentInfo":290,"targetDuration":60,"studyType":293,"phases":294,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":98,"whyStopped":60,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":315},{"fullName":5,"class":6},"Locus Biosciences","INDUSTRY",[8,15,20,25,30],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1- Arm 4 (previously 1)","EXPERIMENTAL","Intraurethral (IU) LBP-EC01 on D1 and D2 with intravenous (IV) LBP-EC01 (1x10\\^11 PFU) and oral TMP\u002FSMX on D1 through D3.",[13,14],"Drug: LBP-EC01 0.1 x IV dose","Drug: TMP\u002FSMX",{"label":16,"type":10,"description":17,"interventionNames":18},"Part 1- Arm 5 (previously 2)","Intraurethral (IU) LBP-EC01 on D1 and D2 with intravenous (IV) LBP-EC01 (1x10\\^10 PFU) and oral TMP\u002FSMX on D1 through D3.",[19,14],"Drug: LBP-EC01 0.01x IV Dose",{"label":21,"type":10,"description":22,"interventionNames":23},"Part 1- Arm 6 (previously 3)","Intraurethral (IU) LBP-EC01 on D1 and D2 with intravenous (IV) LBP-EC01 infusion (1x10\\^12 PFU) and oral TMP\u002FSMX on D1 through D3.",[24,14],"Drug: LBP-EC01 IV Infusion Dose",{"label":26,"type":10,"description":27,"interventionNames":28},"Part 2: LBP-EC01","LBP-EC01 given by dose regimen selected from Part 1. IU LBP-EC01 on D1 and D2 with IV LBP-EC01 (1x10\\^11 PFU) and oral TMP\u002FSMX on D1 through D3.",[29,14],"Drug: LBP-EC01",{"label":31,"type":32,"description":33,"interventionNames":34},"Part 2: Placebo","PLACEBO_COMPARATOR","Placebo given by dose regimen selected from Part 1. IU placebo on D1 and D2 with IV placebo and oral TMP\u002FSMX on D1 through D3.",[35,14],"Drug: Placebo",[37,44,50,56,61,65],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"DRUG","LBP-EC01 0.1 x IV dose","Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.6mL of LBP-EC01 (approximately 1x10\\^11 PFU) diluted in 0.4mL of Lactated Ringer's solution given on Days 1 through Day 3.",[9],[43],"1x10^11 PFU IV dose",{"type":38,"name":45,"description":46,"armGroupLabels":47,"otherNames":48},"LBP-EC01 0.01x IV Dose","Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.06 mL of LBP-EC01 (approximately 1x10\\^10 PFU) diluted in 0.94 mL of Lactated Ringer's solution given on Days 1 through Day 3.",[16],[49],"1x10^10 PFU IV Dose",{"type":38,"name":51,"description":52,"armGroupLabels":53,"otherNames":54},"LBP-EC01 IV Infusion Dose","Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous infusion dose of 6mL of LBP-EC01 (approximately 1x10\\^12 PFU) diluted in 94 mL of Lactated Ringer's solution given over 2 hours on Days 1 through Day 3.",[21],[55],"1x10^12 PFU IV Infusion Dose",{"type":38,"name":57,"description":58,"armGroupLabels":59,"otherNames":60},"Placebo","Dose regimen selected from Part 1 of placebo (Tris buffer).",[31],null,{"type":38,"name":62,"description":63,"armGroupLabels":64,"otherNames":60},"LBP-EC01","Dose regimen selected from Part 1 of LBP-EC01 (1x10\\^10 - 1x10\\^13 PFU) per dose.",[26],{"type":38,"name":66,"description":67,"armGroupLabels":68,"otherNames":60},"TMP\u002FSMX","TMP\u002FSMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.",[9,16,21,26,31],[70],{"name":71,"affiliation":5,"role":72},"Paul Kim","STUDY_DIRECTOR",[74,79],{"name":75,"role":76,"phone":77,"phoneExt":60,"email":78},"Locus Clinical Operations","CONTACT","(919) 495-4510","clinicaloperations@locus-bio.com",{"name":71,"role":76,"phone":77,"phoneExt":60,"email":80},"Paul.kim@locus-bio.com",[82,96,109,121,130,142,154,166,179,191,200,212,220,232,242,252,265],{"facility":83,"status":84,"city":85,"state":86,"zip":87,"country":88,"countryCode":89,"cosmosGeoPoint":90,"geoPoint":95,"contacts":60},"Research Site 138","COMPLETED","Fresno","California","93710","United States","US",{"type":91,"coordinates":92},"Point",[93,94],-119.77237,36.74773,{"lat":94,"lon":93},{"facility":97,"status":98,"city":99,"state":86,"zip":100,"country":88,"countryCode":89,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Research Site 131","RECRUITING","Lancaster","93534",{"type":91,"coordinates":102},[103,104],-118.13674,34.69804,{"lat":104,"lon":103},[107],{"name":108,"role":76,"phone":60,"phoneExt":60,"email":60},"J. Truong, MD",{"facility":110,"status":98,"city":111,"state":86,"zip":112,"country":88,"countryCode":89,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Research Site 123","Los Angeles","90027",{"type":91,"coordinates":114},[115,116],-118.24368,34.05223,{"lat":116,"lon":115},[119],{"name":120,"role":76,"phone":60,"phoneExt":60,"email":60},"J. Kowalczyk",{"facility":122,"status":84,"city":123,"state":86,"zip":124,"country":88,"countryCode":89,"cosmosGeoPoint":125,"geoPoint":129,"contacts":60},"Research Site 125","Montebello","90640",{"type":91,"coordinates":126},[127,128],-118.10535,34.00946,{"lat":128,"lon":127},{"facility":131,"status":98,"city":132,"state":86,"zip":133,"country":88,"countryCode":89,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"Research Site 152","Murrieta","92563",{"type":91,"coordinates":135},[136,137],-117.21392,33.55391,{"lat":137,"lon":136},[140],{"name":141,"role":76,"phone":60,"phoneExt":60,"email":60},"M. Reddy, MD",{"facility":143,"status":98,"city":144,"state":86,"zip":145,"country":88,"countryCode":89,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"Research Site 137","San Diego","92037",{"type":91,"coordinates":147},[148,149],-117.16472,32.71571,{"lat":149,"lon":148},[152],{"name":153,"role":76,"phone":60,"phoneExt":60,"email":60},"L. Burnett, MD",{"facility":155,"status":98,"city":156,"state":86,"zip":157,"country":88,"countryCode":89,"cosmosGeoPoint":158,"geoPoint":162,"contacts":163},"Research Site 126","Tustin","92780",{"type":91,"coordinates":159},[160,161],-117.82617,33.74585,{"lat":161,"lon":160},[164],{"name":165,"role":76,"phone":60,"phoneExt":60,"email":60},"L. Gabal",{"facility":167,"status":98,"city":168,"state":169,"zip":170,"country":88,"countryCode":89,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"Research Site 102","Doral","Florida","33166",{"type":91,"coordinates":172},[173,174],-80.35533,25.81954,{"lat":174,"lon":173},[177],{"name":178,"role":76,"phone":60,"phoneExt":60,"email":60},"B. Penafiel",{"facility":180,"status":98,"city":181,"state":169,"zip":182,"country":88,"countryCode":89,"cosmosGeoPoint":183,"geoPoint":187,"contacts":188},"Research Site 151","Hialeah","33013",{"type":91,"coordinates":184},[185,186],-80.27811,25.8576,{"lat":186,"lon":185},[189],{"name":190,"role":76,"phone":60,"phoneExt":60,"email":60},"C. Sacasa",{"facility":192,"status":84,"city":193,"state":169,"zip":194,"country":88,"countryCode":89,"cosmosGeoPoint":195,"geoPoint":199,"contacts":60},"Research Site 140","Jensen Beach","34957",{"type":91,"coordinates":196},[197,198],-80.22977,27.25449,{"lat":198,"lon":197},{"facility":201,"status":98,"city":202,"state":169,"zip":203,"country":88,"countryCode":89,"cosmosGeoPoint":204,"geoPoint":208,"contacts":209},"Research Site 103","Miami","33176",{"type":91,"coordinates":205},[206,207],-80.19366,25.77427,{"lat":207,"lon":206},[210],{"name":211,"role":76,"phone":60,"phoneExt":60,"email":60},"Y. Rodriguez",{"facility":213,"status":98,"city":202,"state":169,"zip":203,"country":88,"countryCode":89,"cosmosGeoPoint":214,"geoPoint":216,"contacts":217},"Research Site 149",{"type":91,"coordinates":215},[206,207],{"lat":207,"lon":206},[218],{"name":219,"role":76,"phone":60,"phoneExt":60,"email":60},"M. Ramos",{"facility":221,"status":98,"city":222,"state":169,"zip":223,"country":88,"countryCode":89,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"Research Site 153","Ocala","34473",{"type":91,"coordinates":225},[226,227],-82.14009,29.1872,{"lat":227,"lon":226},[230],{"name":231,"role":76,"phone":60,"phoneExt":60,"email":60},"L. Alvarado, MD",{"facility":233,"status":84,"city":234,"state":235,"zip":236,"country":88,"countryCode":89,"cosmosGeoPoint":237,"geoPoint":241,"contacts":60},"Research Site 120","Boston","Massachusetts","02115",{"type":91,"coordinates":238},[239,240],-71.05977,42.35843,{"lat":240,"lon":239},{"facility":243,"status":98,"city":244,"state":245,"zip":246,"country":88,"countryCode":89,"cosmosGeoPoint":247,"geoPoint":251,"contacts":60},"Research Site 154","St Louis","Missouri","63141",{"type":91,"coordinates":248},[249,250],-90.19789,38.62727,{"lat":250,"lon":249},{"facility":253,"status":98,"city":254,"state":255,"zip":256,"country":88,"countryCode":89,"cosmosGeoPoint":257,"geoPoint":261,"contacts":262},"Research Site 145","Raleigh","North Carolina","27708",{"type":91,"coordinates":258},[259,260],-78.63861,35.7721,{"lat":260,"lon":259},[263],{"name":264,"role":76,"phone":60,"phoneExt":60,"email":60},"N. Siddiqui, MD",{"facility":266,"status":84,"city":267,"state":255,"zip":268,"country":88,"countryCode":89,"cosmosGeoPoint":269,"geoPoint":273,"contacts":60},"Research Site 118","Winston-Salem","27157",{"type":91,"coordinates":270},[271,272],-80.24422,36.09986,{"lat":272,"lon":271},{"type":275,"investigatorFullName":60,"investigatorTitle":60,"investigatorAffiliation":60,"oldNameTitle":60,"oldOrganization":60},"SPONSOR",[277],{"name":278,"class":6},"Parexel","100476776","phase-2-a-study-of-lbp-ec01-in-the-treatment-of-acute-uncomplicated-uti-caused-by-drug-resistant-e-coli-eliminate-trial-100476776",false,"NCT05488340","A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)","A Phase 2, Double-blind, Randomized, Active-controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of LBP-EC01 in the Treatment of Acute Uncomplicated Urinary Tract Infection Caused by Drug Resistant E. Coli","ELIMINATE","Inclusion Criteria:\n\n* History of UTI in the past 12 months and prior or current uUTI caused by AMR E. coli (as single pathogen or part of polymicrobial infection where E. coli is the predominant pathogen). Please note that the current infection can be used to meet the requirement of AMR E. coli documentation.\n* Able to supply a mid-stream, clean catch urine sample for microbiological analysis.\n* Active acute uUTI infection defined by:\n\n  a. Evidence of pyuria: i. \\>10 white blood cell (WBC)\u002FmL3 on microscopic evaluation of spun, clean, mid-stream urine specimen or \\>3 WBC\u002Fhigh power field on unspun clean, mid-stream urine specimen, AND\u002FOR ii. Dipstick analysis of a clean, mid-stream urine specimen positive for leukocytes, AND b. At least 2 of the following signs or symptoms of UTI: dysuria, urinary frequency, urinary urgency, or suprapubic pain\n* Willing to comply with all aspects of study design including study restrictions, blood, urine, and stool sampling, and scheduled study visits.\n* All sexually active female patients of childbearing potential must use highly effective contraception during the study and until 2 weeks after the last dose of study drug treatment.\n* Agrees to STOP continuous low dose antimicrobial prophylaxis and\u002For will maintain the same practices for post-coital antimicrobial prophylaxis to prevent UTI, as during the prior 12-months, for the entire study duration (throughout the 6-month follow-up period or study discharge).\n* Agrees to not use any prescription or non-prescription medication for the microbiological or symptomatic treatment of the presenting acute uUTI for the first 10 days of the study.\n* Capable of providing their own signed informed consent form (ICF) prior to any study-related procedures being performed.\n* If participating in Part 1 of the study, agrees to fast for ≥2 h prior to first dose of study drug on Day 1\u002FVisit 1 except for drinking 240 mL of water with study drug administration.\n\nExclusion Criteria:\n\n* Signs or symptoms of systemic illness such as fever greater than 38° Centigrade\u002F Celsius, shaking chills, or other clinical manifestations suggestive of complicated UTI.\n* Treatment with other antibacterial drugs including those that are effective for treatment of the acute uUTI or prevention of recurrent UTI in the 5 days prior to Screening unless the recovered pathogen demonstrates resistance to the initial antibiotic and clinical symptoms persist. In postmenopausal women vaginal estrogen replacement therapy is permitted so long as patient meets all other eligibility criteria, that the dose and regimen has be stable for \\> 3 months from Screening (D1\u002FV1), and that there is no planned change to therapy through the 6-month follow-up period or study discontinuation.\n* Clinical symptoms for more than 5 days before Screening.\n* Presence of indwelling urinary bladder catheters, urinary tract anatomical abnormalities that increase UTI risk or lead to a post void residual (PVR) urine volume \\> 150mL, poorly controlled diabetes mellitus (diagnosed but is not being treated\u002Fmanaged by a physician's care or HbA1c \\>8), current symptomatic or larger than 5mm renal calculi, or advanced renal dysfunction (determined by eGFR \\\u003C 45 mL\u002Fmin\u002F1.73 m2). Patients with vaginal prolapse beyond the hymen with Valsalva (e.g., when coughing).\n* Individuals considered to be immunocompromised.\n* Clinically significant serious unstable physical illness that in the investigator's opinion prevents patient from completing the study or prevents interpretation or resolution of clinical symptoms.\n* Pregnant or nursing women.\n* Exposure to any investigational drugs or other phage therapy 30 days prior to Screening (D1\u002FV1) or prior to participation in this study. Patients who participate in Part 1 are not eligible for participation in Part 2.\n* Allergies to excipients of the study drug or antibiotics.\n* History of autonomic dysreflexia.\n* History of intravenous (IV) drug abuse or is currently using or has positive results for drugs of abuse at screening.\n* Patients who reside in a long-term care facility.\n* Suspected or confirmed acute coronavirus disease 2019 (COVID-19) or recent COVID-19 infection with ongoing symptoms.","FEMALE","18 Years","75 Years",{"count":291,"type":292},318,"ESTIMATED","INTERVENTIONAL",[295],"PHASE2","This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the subsequent 288 patient blinded portion of the study which will be randomized 1:1 comparing LBP-EC01 + antibiotic versus placebo + antibiotic in patients with a history of prior urinary tract infection (UTI) cased by E. coli. All patients will be required to have an active acute uncomplicated UTI at baseline.",[298],"Urinary Tract Infections",[62,300,301,302,303,304,305],"Urinary tract infection","E. coli","Bacteriophage","Phage","crPhage","Recombinant bacteriophage","2026-03-18",{"date":308,"type":309},"2026-03-20","ACTUAL",{"date":311,"type":309},"2022-07-13",{"date":313,"type":292},"2026-12",{"name":5,"class":6},17]